Data Analytics, Mining, Pharmaceuticals, small cap, technology, UK Equities
GSK and AstraZeneca were top performers with strong earnings and guidance raises. GSK raised 2025 sales and earnings guidance after double-digit growth from specialty HIV and oncology drugs. AstraZeneca benefited from pricing agreement optimism and reiterated low double-digit core EPS growth guidance.
This report provides a detailed summary of investor holdings for a
specified stock ticker, highlighting key metrics such as fund
name, total assets under management (AUM), invested value,
portfolio weight, and shares owned. It also tracks changes in
share ownership during the last quarter, including the percentage
of shares bought or sold and the percentage of outstanding shares
owned. The data is generated using an API that processes investor
holdings and calculates these values for each fund. This report
helps investors and analysts monitor the stock positions of major
funds, identify investment trends, and assess the influence of
large investors on individual stocks.
